The cancer drug technology attracting billions in investment just got a significant manufacturing upgrade
Antibody-drug conjugates are one of the most exciting and fastest-growing categories in cancer treatment. The concept is elegant: take a highly targeted antibody that seeks out cancer cells specifically, attach a potent cancer-killing drug to it, and deliver that drug precisely where it is needed while sparing healthy tissue. The challenge is in the attach part. How you connect the drug to the antibody determines how well the medicine works, how safe it is, and whether it can be manufactured consistently at commercial scale. On March 31, 2026, NJ Bio and Ajinomoto Bio-Pharma Services announced a collaboration to bring Aji Bio-Pharma’s AJICAP technology platform into NJ Bio’s drug discovery and development workflows, expanding access to one of the most advanced site-specific conjugation technologies available to early-stage biopharma companies.
For the biotech companies working on the next generation of targeted cancer therapies, this partnership makes a previously difficult-to-access technology significantly more available.
Why antibody-drug conjugates are one of the most important areas in oncology right now
ADCs have moved from a promising concept to a validated treatment modality over the past decade. The FDA has approved more than a dozen ADCs for various cancers, and the pipeline of ADCs in clinical development has expanded dramatically. According to Nature Reviews Drug Discovery, the ADC market is projected to exceed $20 billion annually by the late 2020s, with dozens of programs in late-stage clinical development across breast cancer, lung cancer, blood cancers, and other indications.
The commercial success of drugs like Enhertu, developed by AstraZeneca and Daiichi Sankyo, has validated the ADC approach at the highest level and triggered a wave of investment and partnership activity across the sector. Major pharmaceutical companies have spent tens of billions of dollars acquiring ADC-focused biotechs and licensing ADC programs over the past three years, reflecting the industry’s conviction that targeted drug delivery represents a fundamental advance in cancer treatment.
What drives that interest is the therapeutic index improvement. Conventional chemotherapy kills cancer cells but also damages healthy tissue, causing the side effects that make cancer treatment so difficult for patients. An ADC targets a specific protein expressed on cancer cells, delivers its cytotoxic payload there, and ideally leaves healthy cells unharmed. When it works, it is dramatically more effective and better tolerated than conventional chemotherapy.
What site-specific conjugation means and why it matters so much
The original ADC designs attached drug molecules to antibodies randomly, at multiple different sites across the antibody’s surface. That random attachment created a heterogeneous mixture of products with different drug-to-antibody ratios, different pharmacokinetic properties, and inconsistent therapeutic activity. Manufacturing consistency was difficult. Predicting clinical behavior from preclinical data was unreliable.
Site-specific conjugation solves that problem by attaching the drug payload at precisely defined locations on the antibody. The result is a homogeneous product with a controlled drug-to-antibody ratio, predictable pharmacokinetics, and consistent therapeutic activity. Better defined chemistry means more reliable manufacturing, cleaner regulatory submissions, and stronger correlation between preclinical and clinical results.
AJICAP achieves site-specific conjugation at defined lysine residues on the antibody without requiring any engineering of the antibody itself. That last point is significant. Many site-specific conjugation approaches require modifying the antibody sequence, which adds time, cost, and development risk. AJICAP works with standard antibodies, preserving their structure and function while achieving the precision that site-specific conjugation requires.
According to the American Chemical Society’s medicinal chemistry publications, site-specific ADC conjugation consistently outperforms random conjugation approaches in preclinical models for therapeutic index, stability, and pharmacokinetic consistency. The clinical data emerging from site-specific ADCs is beginning to reflect those advantages.
What NJ Bio brings to the partnership and who benefits
NJ Bio is a contract research and development organization headquartered in Princeton, New Jersey, with chemistry facilities in Bristol, Pennsylvania and Mumbai, India. It specializes in bioconjugation, synthetic organic chemistry, protein-based biopharmaceuticals, and GMP manufacturing for ADCs, targeted protein degraders, oligonucleotide conjugates, and other complex therapeutic categories. The organization has been recognized as Best Contract Research Organization at the World ADC Conference for multiple consecutive years.
For small and mid-size biopharma companies that cannot justify building their own bioconjugation infrastructure, NJ Bio provides access to the specialized capabilities that ADC development requires without the capital investment of an internal platform. Adding AJICAP to that offering means NJ Bio’s clients now have access to site-specific conjugation technology that was previously difficult to access outside of well-resourced larger companies or direct relationships with Ajinomoto.
Ajinomoto Bio-Pharma Services brings manufacturing scale, regulatory experience, and platform technology built across sites in Belgium, India, Japan, and the United States. AJICAP is already established as a production platform, not just a research tool, which means programs that advance through discovery and into development can scale manufacturing without changing conjugation technology mid-program. That continuity reduces technical and regulatory risk at exactly the stage where programs are most vulnerable to costly delays.
The broader significance for the ADC field
One of the consistent challenges in ADC development is that access to advanced conjugation technologies has been disproportionately concentrated in large pharmaceutical companies with the resources to develop proprietary platforms or negotiate exclusive technology access. Smaller biotechs, which generate a significant proportion of innovative drug candidates, have often been forced to use older random conjugation approaches or accept the overhead of direct platform negotiations with technology holders.
This partnership between NJ Bio and Ajinomoto Bio-Pharma Services is a deliberate step toward democratizing access to site-specific conjugation at the discovery stage. When early-stage programs are built on better conjugation chemistry from the outset, the quality of data generated in discovery is higher, the path to clinical development is cleaner, and the probability of success increases.
The FDA’s Center for Drug Evaluation and Research has highlighted manufacturing consistency and characterization of complex biologics as among the most important factors in successful regulatory submissions for ADC products. Programs developed on AJICAP from early discovery have a cleaner manufacturing history to present to regulators than those built on heterogeneous random conjugation approaches.
Sources
- Nature Reviews Drug Discovery — ADC Market Analysis
- American Chemical Society — Journal of Medicinal Chemistry
- FDA — Drug Development and Approval Process
- NJ Bio — Official Website
- Ajinomoto Bio-Pharma Services — Official Website
Editorial disclosure
This article is based on a press release issued by Ajinomoto Bio-Pharma Services and has been independently rewritten and editorially expanded. It covers a research collaboration between NJ Bio and Ajinomoto Bio-Pharma Services for the integration of the AJICAP site-specific conjugation platform into NJ Bio’s drug discovery and development services. This article discusses pharmaceutical research and development technologies. It does not constitute medical advice. All ADC programs discussed are in discovery or early development stages. Market context is sourced from Nature Reviews Drug Discovery, the American Chemical Society, and the FDA. Commentary reflects the author’s own assessment. The information provided on this website is for informational and educational purposes only. Our content is derived strictly from verified online sources to ensure accuracy and objectivity. This analysis does not constitute financial, investment, or professional advice. Readers are encouraged to consult with qualified professionals before making decisions based on this information. For more information, please see our full DISCLAIMER.
